Refractory Multiple Myeloma Clinical Trials in Rochester, Minnesota
7 recruitingRochester, Minnesota
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled116 locationsNCT07391657
Recruiting
Phase 1
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
National Cancer Institute (NCI)26 enrolled14 locationsNCT06465316
Recruiting
Phase 2
MMRC Horizon One: RRMM (MMRC-099)
Refractory Multiple MyelomaRelapse Multiple Myeloma
Multiple Myeloma Research Consortium300 enrolled13 locationsNCT06171685
Recruiting
Phase 1Phase 2
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234
Recruiting
Not Applicable
Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Mayo Clinic20 enrolled1 locationNCT07045727
Recruiting
Phase 1
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.130 enrolled11 locationsNCT06375044
Recruiting
Phase 2
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Mayo Clinic44 enrolled1 locationNCT06940297